Roivant valued at $7B in blank-check merger, bucking SPAC slowdown
Bio Pharma Dive
MAY 3, 2021
Vivek Ramaswamy's unusual biotech holding company will go public through a deal with Montes Archimedes Acquisition Corp. that nets Roivant $611 million.
Let's personalize your content